MolDX: Melanoma Risk Stratification Molecular Testing

Melanoma risk-stratification molecular tests are covered for patients with a personal history of melanoma who are undergoing workup or treatment evaluation, are non-metastatic, and have either stage T1b+ or T1a with documented microstaging concern, provided the presumed SLNB positive risk exceeds 5% and the patient's disease parameters fall within the test's intended use. Coverage requires that the specific test demonstrate clinical validity, clinical utility beyond standard clinical/histologic/radiographic factors, appropriate analytical validity, and performance equivalent or superior to other covered tests, with supporting documentation in the medical record.

"Patient has a personal history of melanoma."

Sign up to see full coverage criteria, indications, and limitations.